Treatment of Asthma
Inhaled corticosteroids (ICS) are the most effective long-term control medication for persistent asthma and should be the foundation of treatment for all patients, with short-acting beta-agonists (SABA) reserved for quick relief—never as monotherapy. 1
Long-Term Management: Stepwise Approach
Step 1: Intermittent Asthma
- Preferred: As-needed low-dose ICS-formoterol (anti-inflammatory reliever) 2
- This represents a major shift from SABA-only treatment, which is no longer recommended due to increased exacerbation risk
- For patients with symptoms <2 times/month, no nocturnal symptoms, FEV1 >80% predicted
Step 2: Mild Persistent Asthma
- Preferred: Low-dose ICS daily 1, 3
- Alternative: Leukotriene receptor antagonists (montelukast, zafirlukast) if patient unable/unwilling to use ICS 1
- Advantages: once-daily dosing, high compliance rates, good symptom control in many patients
- However, less effective than ICS for most patients
Step 3: Moderate Persistent Asthma
- Two equally preferred options 1:
- Low-dose ICS + long-acting beta-agonist (LABA)
- Medium-dose ICS alone
Critical safety warning: LABAs must NEVER be used as monotherapy—only in combination with ICS 3, 1. The FDA has issued a black-box warning due to increased severe exacerbations and deaths when LABAs are used alone.
For patients ≥12 years, adding LABA to low-dose ICS is preferred over adding leukotriene receptor antagonists 1.
Steps 4-6: Severe Persistent Asthma
- High-dose ICS + LABA
- Consider adding:
Important monitoring: Use of SABA >2 days/week for symptom relief (excluding exercise prevention) indicates inadequate control and need to step up anti-inflammatory therapy 1.
Acute Exacerbations
Mild to Moderate Exacerbations
- Inhaled SABA: 2-4 puffs every 20 minutes for up to 3 doses 6
- Can use up to 8 inhalations if using budesonide-formoterol as maintenance therapy 5
- Oral corticosteroids if inadequate response:
Severe Exacerbations (FEV1 or PEF <40% predicted)
- Oxygen to maintain saturation >90%
- High-dose SABA: Nebulized albuterol 2.5-5 mg every 20 minutes for 3 doses 6
- Ipratropium bromide: Add 0.5 mg nebulized every 20 minutes for 3 doses in emergency setting 3, 6
- Provides additive benefit in moderate-severe exacerbations
- Should NOT be continued once hospitalized
- Systemic corticosteroids: Oral preferred over IV (no advantage to IV route) 1, 7
- Magnesium sulfate or heliox for severe exacerbations unresponsive to initial treatment 3
Critical pitfall: Doubling the dose of ICS at home for exacerbations is NOT effective—use oral corticosteroids instead 3.
Key Medication Principles
Inhaled Corticosteroids
- Most potent and consistently effective controller medication 1
- Low-dose ICS is generally safe with minimal systemic effects
- High-dose ICS (>2000 mcg beclomethasone equivalent daily) may cause:
- Reduced linear growth in children
- Lower bone mineral density
- Increased pneumonia risk 5
- Local side effects: oral candidiasis (use spacer, rinse mouth), dysphonia, cough
Long-Acting Beta-Agonists
- Duration >12 hours (salmeterol, formoterol)
- Never use as monotherapy 3, 1
- Preferred adjunct to ICS in patients ≥12 years
- Bronchoprotective effect wanes with regular use (exercise-induced bronchoconstriction)
Leukotriene Receptor Antagonists
- Montelukast (≥1 year), zafirlukast (≥7 years)
- Alternative to ICS for mild persistent asthma
- Can attenuate exercise-induced bronchoconstriction
- May be more effective in aspirin-induced asthma 8
Essential Non-Pharmacologic Management
- Patient education at every visit, not just separate programs 3
- Inhaler technique training regularly—poor technique is a major cause of treatment failure 9
- Environmental control: multifaceted approach to reduce allergen/irritant exposure 3
- Allergen immunotherapy: Consider for steps 2-4 when clear allergen relationship exists 3
- Written action plan with specific PEF thresholds for stepping up treatment 9
Follow-Up and Monitoring
- Every 2-4 weeks after initiating treatment
- Every 1-3 months once controlled 5
- Assess: symptom control, lung function, inhaler technique, adherence, SABA use frequency
- Step down therapy after 3 months of good control by reducing ICS dose 25-50% 7
- Step up if using SABA >2 days/week or having nocturnal symptoms
High-Risk Patients Requiring Specialist Referral
- History of intubation/mechanical ventilation
- Hospitalization or ED visit in past year
- Currently using or recently stopped oral corticosteroids
- Using >1 canister SABA per month
- Symptoms despite high-dose ICS therapy
- Psychiatric illness or poor adherence 5